Company intelligence / Profile preview

MZT Holdings

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

MZT Holdings is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for the treatment of advanced solid tumors. The company's lead candidate, MZT-101, is a next-generation microtubule-targeting agent designed to overcome resistance mechanisms common in traditional taxane-based therapies. By utilizing a unique binding mechanism, MZT-101 aims to provide enhanced efficacy and a more favorable safety profile for patients with metastatic breast cancer and non-small cell lung cancer. MZT Holdings is currently advancing its pipeline through early-phase clinical trials to validate its approach in oncology.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on MZT Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MZT Holdings.

Explore the full profile